Etodolac

Etodolac

Clinical data
ATC code	M01AB08 (WHO)
Pharmacokinetic data
Protein binding	100%
Elimination half-life	7.3 ± 4.0 hours
Identifiers
IUPAC name 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid
CAS Number	41340-25-4
PubChem CID	3308
DrugBank	APRD00067
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H21NO3
Molar mass	287.354 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

WikiDoc Resources for Etodolac
Articles
Most recent articles on Etodolac Most cited articles on Etodolac Review articles on Etodolac Articles on Etodolac in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Etodolac Images of Etodolac Photos of Etodolac Podcasts & MP3s on Etodolac Videos on Etodolac
Evidence Based Medicine
Cochrane Collaboration on Etodolac Bandolier on Etodolac TRIP on Etodolac
Clinical Trials
Ongoing Trials on Etodolac at Clinical Trials.gov Trial results on Etodolac Clinical Trials on Etodolac at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Etodolac NICE Guidance on Etodolac NHS PRODIGY Guidance FDA on Etodolac CDC on Etodolac
Books
Books on Etodolac
News
Etodolac in the news Be alerted to news on Etodolac News trends on Etodolac
Commentary
Blogs on Etodolac
Definitions
Definitions of Etodolac
Patient Resources / Community
Patient resources on Etodolac Discussion groups on Etodolac Patient Handouts on Etodolac Directions to Hospitals Treating Etodolac Risk calculators and risk factors for Etodolac
Healthcare Provider Resources
Symptoms of Etodolac Causes & Risk Factors for Etodolac Diagnostic studies for Etodolac Treatment of Etodolac
Continuing Medical Education (CME)
CME Programs on Etodolac
International
Etodolac en Espanol Etodolac en Francais
Business
Etodolac in the Marketplace Patents on Etodolac
Experimental / Informatics
List of terms related to Etodolac

Overview

Etodolac, International Nonproprietary Name (INN) of 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid (empirical formula C₁₇H₂₁NO₃), also sold under the trade name Lodine is a non-steroidal anti-inflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body. As a group, NSAIDs are non-narcotic relievers of mild to moderate pain of many causes, including injury, menstrual cramps, arthritis, and other musculoskeletal conditions. Since the response to different NSAIDs varies from patient to patient, it is not unusual for a Doctor or General practitioner (GP) to try different NSAIDs for any given condition.

Etodolac is manufacturered by Shire under the tradename Lodine SR. Etodolac is also available as a generic.

Preparations

capsules: 200mg, 300mg; tablets: 400mg, 500mg and XL formulations as 400mg and 600mg.

Prescribed for

Etodolac is used for the treatment of inflammation and pain caused by osteoarthritis and rheumatoid arthritis, as well as soft tissue injuries, such as tendinitis and bursitis. Etodolac is also used for rapid relief of moderate to severe pain, such as with menstrual cramps.

Dosing

Should be taken with food.

Interactions

Etodolac should be avoided by patients with a history of asthma attacks, hives, or other allergic reactions to aspirin or other NSAIDs. Rare but severe allergic reactions have been reported in such individuals. It also should be avoided by patients with peptic ulcer disease or poor kidney function, since this medication can aggravate both conditions. Etodolac is generally used with caution in patients taking blood thinning medications (anticoagulants), such as warfarin (Coumadin), because of increased risk of bleeding. Patients taking lithium can develop toxic blood lithium levels. Patients also taking ciclosporin (Sandimmune) can develop kidney toxicity. Use in children has not been adequately studied. Etodolac is not habit-forming. NSAIDs should be discontinued prior to elective surgery because of a mild interference with clotting that is characteristic of this group of medicines. Etodolac is best discontinued at least four days in advance of the procedure.

Persons who have more than 3 alcoholic beverages per day are at increased risk of developing stomach ulcers when taking etodolac or other NSAIDs.

Pregnancy

Etodolac is generally avoided during pregnancy.

Nursing mothers

Etodolac is generally avoided in nursing mothers.

Side Effects

Etodolac may cause side effects, or Adverse drug reaction. Tell your doctor if any of these symptoms are severe or do not go away:

constipation, diarrhea, gas or bloating, vomiting, headache, dizziness, ringing in the ears, runny nose, sore throat, blurred vision.

Some side effects can be serious. If you experience any of the following symptoms, or those mentioned in the IMPORTANT WARNING section, call your doctor immediately. Do not take any more etodolac until you speak to your doctor:

unexplained weight gain, swelling of the eyes, face, lips, tongue, throat, hands, feet, ankles, or lower legs, fever or chills, blisters, rash, itching, hives, hoarseness, difficulty breathing or swallowing, yellowing of the skin or eyes, excessive tiredness, unusual bleeding or bruising, lack of energy, loss of appetite, pain in the upper right part of the stomach, flu-like symptoms, pale skin, fast heartbeat, cloudy, discolored, or bloody urine, difficult or painful urination, back pain.

Etodolac may cause other side effects.

Sold under the name Etogesic for veterinary use

References

• DrugBank info
• [3]

External links

• Information on Etodolac from rxlist.com